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The dystroglycanopathies (DGpathies) are a clinically and genetically diverse group of recessively inherited 
conditions ranging from the most severe Walker-Warburg syndrome (WWS), to mild forms of adult onset limb 
girdle muscular dystrophy (LGMD). The LGMD2I caused by the L276I mutation in fukutin-related protein 
(FKRP) is common in the Caucasians population. Their hallmark is a reduction in the functional O-glycosylation 
of α-dystroglycan. Unfortunately in about 50% of the patient's disease genes are unknown. Curative treatments are 
not available. To this end, we pursued a translational approach: 
By whole exome sequencing, we have discovered 3 new genes (ISPD, B3GALNT2 and GMPPB). The biochemical 
function of isoprenoid synthase domain containing (ISPD) in mammals remain unknown. Remarkably, we 
identified a novel DGpathy phenotype harbouring mutations in ISPD characterized by LGMD, oculomotor apraxia, 
myopia and cerebellar hypoplasia. 
To explore the possible effects of missense mutations, we have mapped them onto the homology model of human 
ISPD derived from the structure of a related bacterial protein (CDP-ME synthase; 1VPA). Of the four mutations 
identified in catalytic domain, two (A53TD and R126H) are predicted to significantly affect the catalytic activity of 
human ISPD whereas the mutations P149L and Y226C are likely to perturb the nearby secondary structure leading 
to destabilization of the mutant protein. We have expressed recombinant His-tagged wt and mut. ISPD protein in 
E.coli and purified Co-IMAC affinity chromatography. By the use of Thermofluor we could confirm the 
differences in the stability between wt and mut. ISPD proteins. 
To enable clinical trials, we performed a pilot study for the discovery of serum biomarkers in LGMD2I and could 
identify various candidates which we grouped into a) myofibrillar proteins b) glycolytic enzymes, c) extracellular 
matrix and d) other muscle specific proteins. 
